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Abstract 
Background: The prognostic values of staging parameters require continual re‑assessment amid changes in diag‑
nostic and therapeutic methods. This study aimed to identify the prognostic factors and failure patterns of non‑meta‑
static nasopharyngeal carcinoma (NPC) in the intensity‑modulated radiotherapy (IMRT) era.
Methods: We reviewed the data from 749 patients with newly diagnosed, biopsy‑proven, non‑metastatic NPC in our 
cancer center (South China, an NPC endemic area) between January 2003 and December 2007. All patients under‑
went magnetic resonance imaging (MRI) before receiving IMRT. The actuarial survival rates were estimated using the 
Kaplan–Meier method, and survival curves were compared using the log‑rank test. Multivariate analyses with the 
Cox proportional hazards model were used to test for the independent prognostic factors by backward eliminating 
insignificant explanatory variables.
Results: The 5‑year occurrence rates of local failure, regional failure, locoregional failure, and distant failure were 
5.4, 3.0, 7.4, and 17.4%, respectively. The 5‑year survival rates were as follows: local relapse‑free survival, 94.6%; nodal 
relapse‑free survival, 97.0%; distant metastasis‑free survival, 82.6%; disease‑free survival, 75.1%; and overall survival, 
82.0%. Multivariate Cox regression analysis revealed that orbit involvement was the only significant prognostic fac‑
tor for local failure (P = 0.011). Parapharyngeal tumor extension, retropharyngeal lymph node involvement, and the 
laterality, longest diameter, and Ho’s location of the cervical lymph nodes were significant prognostic factors for both 
distant failure and disease failure (all P < 0.05). Intracranial extension had significant prognostic value for distant failure 
(P = 0.040).
Conclusions: The key failure pattern for NPC was distant metastasis in the IMRT era. With changes in diagnostic and 
therapeutic technologies as well as treatment modalities, the significant prognostic parameters for local control have 
also been altered substantially.
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Background
Nasopharyngeal carcinoma (NPC) is a challenge in 
oncology. Due to the deep-seated anatomic location and 
proximity of NPCs to critical structures, radical surgical 
resection is extremely difficult [1]. The introduction of 
radiotherapy has made this otherwise lethal malignant 
disease curable [1]. However, radiotherapy has undergone 
several different periods of development, and it was not 
until the advent of mega-voltage machines that a 5-year 
overall survival (OS) rate of 25% was first achieved, which 
marked the first major breakthrough in the treatment of 
NPC and established radiotherapy as the primary modal-
ity of choice for NPC [2].
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Since that time, progressive improvements in the 
treatment outcomes of patients with NPC have been 
achieved. Initially, in the 1970–1980s, conventional radi-
otherapy alone resulted in similar outcomes in both the 
endemic and non-endemic areas, with 5-year OS rates 
of 48%–52%, a cumulative local failure rate of 20%, a 
cumulative regional failure rate of 14%, and a cumulative 
distant metastasis rate of 19% [3, 4]. During the 1990s, 
rapid technological advances in imaging methods, com-
puterized planning systems, and radiotherapy facilities 
and the accumulation of radiobiological knowledge that 
enabled schedule, dose, and fractionation optimization 
led to better outcomes after radiotherapy, with 5-year OS 
rates of 65%–74%, a cumulative local failure rate of 12%, 
a regional failure rate of 5%, and a distant metastasis rate 
of 16% [5, 6]. However, local relapse and distant metas-
tasis remained the two major causes of failure. Intensity-
modulated radiotherapy (IMRT) was introduced in the 
2000s and represented a major breakthrough in the radi-
otherapeutic management of NPC. Due to the dosimetric 
advantages of IMRT combined with the use of magnetic 
resonance imaging (MRI)-guided tumor volume delinea-
tion and concurrent chemotherapy, local control rate in 
NPC patients has improved significantly [7, 8].
With these changes in diagnostic and therapeutic tech-
nologies, the significant prognostic parameters that have 
been identified in patients treated with conventional radi-
otherapy may also have been altered substantially. There-
fore, caution must be applied when applying prognostic 
factors to predict prognosis and guide treatment strate-
gies in patients treated using these modern, more effec-
tive treatment modalities [9]. Thus, the prognostic values 
of staging parameters require continual re-assessment 
amid these changes in diagnostic and therapeutic meth-
ods. However, few studies have systematically inves-
tigated the prognostic factors in NPC in the IMRT era. 
We performed a retrospective systematic evaluation of 
a large cohort of patients with NPC who were treated 
with IMRT at the Sun Yat-sen University Cancer Center 
in South China, an NPC endemic area. The aim of this 
study was to identify the key failure patterns and prog-
nostic factors to improve the treatment of patients with 
NPC and provide a baseline for future studies.
Methods
Patient cohort
We reviewed the medical records of all patients with NPC 
treated with IMRT at the Sun Yat-sen University Cancer 
Center between January 2003 and December 2007. We 
included all patients with newly diagnosed, non-meta-
static, histologically confirmed disease. All patients were 
staged using a standard protocol [10] comprising a com-
plete disease history, physical examination, hematology 
and biochemistry profiles, fiberoptic nasopharyngos-
copy, MRI of the neck and nasopharynx, chest radiogra-
phy, abdominal sonography, and a whole-body bone scan 
using single-photon emission computed tomography 
(SPECT). All MRI materials and clinical records were 
reviewed to minimize heterogeneity in restaging. The 
study was reviewed and approved by the ethics commit-
tee of the Sun Yat-sen University Cancer Center.
Image assessment and criteria for staging parameters
Two radiologists specializing in head and neck cancers 
evaluated all scans separately. All parameters included 
in the TNM staging were re-assessed, and any disagree-
ments were resolved by consensus. Parapharyngeal 
tumor extension was identified as a direct tumor exten-
sion through the pharyngobasilar fascia [11]. Nasal cav-
ity extension was defined as tumor extension beyond the 
bony nasal septum [12]. Oropharyngeal extension was 
defined as the primary tumor extension of the mucosa 
or submucosal tissue below the plane of the superior 
surface of the soft palate or the C1–C2 interspace [13]. 
Hypopharyngeal extension was defined as the primary 
tumor extension of the mucosa or submucosal tissue to 
the superior border of the epiglottis or lower margin of 
the C3 interspace [14]. The skull base included the cli-
vus, pterygoid bones, body of the sphenoid, apices of the 
petrous temporal bones, sphenoid wings, upper cervical 
spine, and skull base foramina and fissures [15]. The cri-
terion for orbit extension was tumor extension into the 
orbital apex, inferior orbital fissure, or superior orbital 
fissure [16]. Involvement of the cavernous sinus, brain 
tissue, cistern, or dural meninges was interpreted as 
intracranial extension [17].
The diagnostic criteria for metastatic lymphadenopa-
thy [18] include the following: (a) lateral retropharyngeal 
lymph nodes with a minimal axial diameter in the largest 
plane of an individual node of at least 5 mm and any node 
observed in the median retropharyngeal group, lymph 
nodes with a minimal axial diameter of at least 11 mm in 
the jugulodigastric region and 10 mm for all other cervi-
cal nodes; (b) lymph nodes of any size with central necro-
sis or a contrast-enhanced rim; (c) nodal groups, defined 
as the presence of three or more contiguous and con-
fluent lymph nodes, each of which with a minimal axial 
diameter of 8–10  mm; and/or (d) lymph nodes of any 
size with extracapsular spread, the presence of indistinct 
nodal margins, irregular nodal capsular enhancement, or 
infiltration into the adjacent fat or muscle.
Treatment
All patients underwent radical radiotherapy. The naso-
pharyngeal and upper neck tumor volumes were treated 
using IMRT for the entire treatment course. The lower 
Page 3 of 10Mao et al. Chin J Cancer  (2016) 35:103 
neck was treated with a conventional anterior or anter-
oposterior opposing cervical technique. The prescribed 
doses were 68  Gy to the planning target volume of the 
primary tumor (PTV-P), 60–68  Gy to the PTV of the 
nodes (PTV-N), 60 Gy to the high-risk regions (PTV1), 
and 54  Gy to the low-risk regions (PTV2) in 30 frac-
tions over 6 weeks. The anterior split-neck field received 
50–60  Gy irradiation in 2-Gy fractions. The irradiation 
was delivered once daily for 5  days per week. Further 
details of the IMRT techniques used at our cancer center 
have been previously reported [10].
During the study period, concurrent chemoradiother-
apy was recommended for stage III to IVa-b disease, and 
no chemotherapy was recommended for stage I to IIa 
disease (as defined using the 6th edition of the Interna-
tional Union against Cancer/American Joint Committee 
on Cancer [UICC/AJCC] staging system). However, some 
patients with stage III to IVa–b disease also received neo-
adjuvant or adjuvant chemotherapy, and some patients 
with stage IIb disease received concurrent chemora-
diotherapy. Neoadjuvant or adjuvant chemotherapy 
consisted of cisplatin (80–100 mg/m2) with either 5-fluo-
rouracil (800–1000  mg/m2) or taxanes (paclitaxel [135–
175 mg/m2] or docetaxel [70–75 mg/m2]) every 3 weeks 
for 3 cycles. Concomitant chemotherapy consisted of 
cisplatin (80–100 mg/m2) given on weeks 1, 4, and 7 of 
radiotherapy or cisplatin (30–40  mg/m2) given weekly. 
When possible, salvage treatments, such as intracavitary 
brachytherapy, surgery, and chemotherapy, were pro-
vided in the event of documented relapse or persistent 
disease.
Follow‑up
Treatment responses and toxicity were assessed in each 
patient every week during treatment, every 2–3 months 
during the first 2  years after treatment, and then every 
3–6  months during the following 3  years. Endoscopy, 
computed tomography (CT), or MRI scans of the head 
and neck were also performed every 3 months in the first 
year and annually thereafter. Additional tests were per-
formed when indicated to evaluate local or distant fail-
ure. The last follow-up time was 30th August 2013.
Statistical analysis
All analyses were performed using SPSS version 16.0 
(SPSS, Chicago, IL, USA). The actuarial rates were esti-
mated using the Kaplan–Meier method, and the survival 
curves were compared using the log-rank test. The fol-
lowing endpoints (measured from the start of treatment 
to the first defined event) were estimated: local relapse-
free survival (LRFS), nodal relapse-free survival (NRFS), 
distant metastasis-free survival (DMFS), disease-free 
survival (DFS), and OS.
Multivariate analyses with the Cox proportional haz-
ards model were used to test for independent prognos-
tic factors by backward elimination of the insignificant 
explanatory variables. The Cox proportional hazards 
model was also used to calculate the hazard ratios (HRs) 
and 95% confidence intervals (CIs). Host factors (age and 
sex) were included as covariates in all tests. Two-tailed P 
values <0.05 were considered statistically significant.
Results
Patient characteristics
The median patient age was 43  years (range, 
13–78  years), and the cohort included 580 males and 
169 females (male:female ratio of 3.4:1). Histologically, 
744 (99.3%) patients had World Health Organization 
(WHO) type II/III disease, and 5 (0.7%) had WHO 
type I disease. Positron emission tomography (PET)/
CT was performed for 162 (21.6%) patients. Using the 
2009 7th UICC/AJCC staging system, the numbers of 
patients with stage I, II, III, IVa, and IVb disease were 
78 (10.4%), 179 (23.9%), 282 (37.7%), 160 (21.3%), and 
50 (6.7%), respectively. The median follow-up duration 
was 81.4  months (range, 3.1–126.5  months). In total, 
424 (86.2%) of the 492 patients with stage III–IV dis-
ease received chemotherapy. The characteristics of the 
patients are summarized in Table 1.
Dose‑volume histogram analysis
Table  2 summarizes the dose-volume histogram (DVH) 
statistics for the target volumes of interest. The maxi-
mum dose (Dmax) and minimum dose (Dmin) of radia-
tion were defined as the maximum and minimum dose 
points in the DVH. The radiation dose prescribed to the 
PTV-P was 68 Gy for all patients. Because the proportion 
of the volume that received <93% of the prescribed dose 
was set to ≤3%, the actual median dose to the PTV-P was 
73.34 Gy.
The dose limitations are  ≤60  Gy to the brainstem 
and  ≤50  Gy to the spinal cord. In some advanced dis-
eases with extensive extension, we would relax the dose 
limitation to Dmax  ≤  63  Gy. The median Dmax for the 
brainstem was 54.16 Gy (range, 31.68–77.65 Gy), and the 
median proportion of the volume in the brainstem that 
received  >60  Gy was 9.67% (range, 0.03%–26.97%). The 
median Dmax for the spinal cord was 33.96  Gy (range, 
8.29–60.54  Gy), and the median proportion of the vol-
ume in the spinal cord that received  >50  Gy was 0.97% 
(range, 0.01%–3.42%). However, 3 of the 749 patients 
received irradiation with a Dmax > 63 Gy, with no serious 
late toxicity for the brainstem. The median doses to the 
left and right parotid glands were 28.20 Gy (range, 11.90–
49.70  Gy) and 29.98  Gy (range, 21.30–42.02  Gy). The 
median proportions of the volumes in the left and right 
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parotid glands that received a dose >26 Gy were 49.34% 
(range, 9.61%–98.25%) and 51.23% (20.59%–96.61%).
Patterns of treatment failure and survival
Among the 749 patients, 56 (7.5%) relapsed [34 (4.5%) 
had local relapse only, 15 (2.0%) had nodal relapse only, 7 
(1.0%) had both local and nodal relapse], and 129 (17.2%) 
had distant metastasis. One hundred forty-nine (19.9%) 
patients died. The median time to relapse was 25.2 
(range, 7.0–93.8) months, and the median time to distant 
metastases was 18.9 (range, 2.6–92.1) months.
The 5-year local failure, regional failure, locoregional 
failure, and distant failure rates for the whole cohort were 
5.4, 3.0, 7.4, and 17.4%, respectively (Fig.  1). The 5-year 
survival rates for the whole cohort were as follows: LRFS, 
94.6%; NRFS, 97.0%; DMFS, 82.6%; DFS, 75.1%; and OS, 
82.0%. Using the 7th edition of the UICC/AJCC stag-
ing system, the 5-year LRFS rates for patients with stage 
T1–T4 NPC were 98.4, 96.2, 93.0, and 90.5%, respec-
tively (Fig.  2a); the 5-year DMFS rates for patients with 
stage N0-N3b NPC were 93.3, 84.2, 72.4, 61.9, and 50.7%, 
respectively (Fig. 2b); and the 5-year OS rates for patients 
with stage I–IVb NPC were 97.4, 93.8, 81.8, 69.7, and 
54.0%, respectively (Fig. 2c).
Prognostic factors
Table 3 lists the factors with independent significance for 
different endpoints. The TNM stage was consistently the 
most significant factor for prognosis prediction: T stage 
for local failure prediction (P  <  0.001), and both T and 
N stages for distant failure, disease failure, and death 
prediction (all P < 0.001). None of the factors had a sig-
nificant influence on nodal failure. An age >50 years was 
associated with significantly higher rates of distant fail-
ure (HR = 1.530, 95% CI 1.037–2.256, P = 0.032), disease 
failure (HR = 1.896, 95% CI 1.403–2.561, P < 0.001), and 
death (HR = 2.482, 95% CI 1.770–3.482, P < 0.001).
The involvement of the nasal cavity, oropharynx, 
parapharynx, skull base, paranasal sinus, cranial nerve 
palsy, intracranial extension, infratemporal fossa, intrac-
ranial extension, orbit, and hypopharynx (all were T 
stage-related parameters) occurred in 280 (37.4%), 85 
(11.3%), 540 (72.1%), 429 (57.3%), 36 (4.8%), 35 (4.7%), 
and 3 (0.4%) patients, respectively. To explore the prog-
nostic values of the specific anatomic factors included 
in the TNM staging system, we analyzed all T stage-
related parameters, all N stage-related parameters (i.e., 
retropharyngeal lymph node involvement as well as 
the laterality, longest diameter, and Ho’s location of the 
involved cervical lymph nodes), age, histological type, 
and chemotherapy modality using univariate and multi-
variate analyses. With the exception of hypopharyngeal 
involvement, the univariate analysis revealed that age, 
histological type, and all T stage- and N stage-related 
parameters were significantly associated with disease 
Table 1 Clinicopathologic features of  the 749 patients 
with nasopharyngeal carcinoma (NPC)
WHO World Health Organization
a According to the 7th edition of the Union for International Cancer Control/
American Joint Committee on Cancer (UICC/AJCC) staging system
Feature No. of patients [cases (%)]
Sex
 Male 580 (77.4)
 Female 169 (22.6)
WHO pathology
 Type I 5 (0.7)
 Type II/III 744 (99.3)
Clinical stagea
 I–II 257 (34.3)
 III–IV 492 (65.7)
T stagea
 T1 177 (23.6)
 T2 140 (18.7)
 T3 264 (35.2)
 T4 168 (22.4)
N stagea
 N0 184 (24.6)
 N1 409 (54.6)
 N2 106 (14.2)
 N3 50 (6.7)
Chemotherapy
 No chemotherapy 214 (28.6)
 Concurrent 243(32.5)
 Induction + concurrent 246 (32.8)
 Concurrent + adjuvant 46 (6.1)
Table 2 Dose-volume histogram data for planning target volumes in the 749 patients with NPC
PTV-P planning target volume of the primary tumor, PTV1 PTV of the high-risk clinical target volume, PTV2 PTV of the low-risk clinical target volume, Dmax maximum 
dose, Dmin minimum dose. All data are presented as median with range in parentheses
Variate Volume (mL) Dmax (Gy) Dmin (Gy) Mean dose (Gy)
PTV‑P 51.89 (2.60–287.48) 79.91 (70.47–93.95) 59.79 (50.58–71.16) 73.11 (68.16–78.48)
PTV1 97.35 (13.78–494.77) 79.67 (72.81–86.08) 58.86 (49.13–67.32) 67.94 (56.66–74.48)
PTV2 368.97 (106.36–685.58) 78.99 (70.04–86.74) 45.28 (43.12–61.47) 60.55 (53.64–72.13)
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failure (all P < 0.05). All factors that were significant in 
univariate analysis were included in the Cox proportion 
hazards model with the backward elimination of non-
significant explanatory variables. Only orbit involve-
ment was found to be significant prognostic factor for 
local failure in the multivariate analysis (P  =  0.011). 
Parapharyngeal involvement, retropharyngeal lymph 
node involvement, and the laterality, longest diameter, 
and Ho’s location of the involved cervical lymph nodes 
were significant prognostic factors for both distant fail-
ure and disease failure (all P < 0.05). Intracranial exten-
sion had significant prognostic value for distant failure 
(P = 0.040) (Table 4).
Discussion
The present study, with 5-year LRFS and DMFS rates of 
94.6% and 82.6%, confirmed that distant metastasis has 
surpassed local relapse to be the major cause of fail-
ure in NPC in the IMRT era, whereas our previous data 
from the conventional radiotherapy era demonstrated 
that both local relapse and distant metastasis were the 
major causes of failure in NPC, with 5-year LRFS and 
DMFS rates of 85% and 81% [6]. Although T stage was 
still a significant predictor for local failure, with the more 
extensive primary extension associated with poorer local 
control, the 5-year LRFS rates for patients with NPC 
at adjacent T stages were not significantly different. T 
stage is becoming less powerful in segregating patients 
into various risk groups. Improvements in local control 
have reduced the significance of known prognostic fac-
tors, even the T stage, for local control prediction [9]. 
It has been recommended that three rather than four T 
stages should be applied to classify patients in the mod-
ern era [19, 20]. In the future, treatment modality may 
be the only significant predictor for local control in NPC 
patients; and the most important challenge in the man-
agement of NPC should be the exploration of more effec-
tive systemic agents to control distant metastasis.
Fig. 1 Cumulative local failure (a), regional failure (b), locoregional failure (c), and distant failure (d) rates of 749 patients with nasopharyngeal carci‑
noma (NPC) who were treated with intensity‑modulated radiation therapy (IMRT)
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Based on CT and conventional radiotherapy, several 
studies have systematically investigated prognostic fac-
tors for local control in patients with NPC [21–23]. Two 
studies have demonstrated that skull base extension or 
cranial nerve palsy could affect local failure-free survival 
[21, 22], whereas one has confirmed that parapharyn-
geal tumor extension was an independent prognostic 
factor for local failure-free survival [23]. Based on MRI 
and IMRT, no systematic data referring to prognostic fac-
tors in patients with NPC were available. Zong et al. [24] 
focused on skull base extension and found that it did not 
influence local failure in the IMRT era. Based on the same 
database presented here, our previous studies reported 
that skull base extension [25] and parapharyngeal tumor 
extension [26] were not independent prognostic factors 
for local control in patients with NPC treated with IMRT. 
In the current study, we systematically re-evaluated all 
of the prognostic factors included in the TNM staging 
system and found that their prognostic values no longer 
remained significant and that orbit involvement was the 
only independent prognostic factor for local control.
Improvements in local control can explain these 
results. First, due to its improved dose conformability and 
escalation, IMRT eliminates the areas at the edges of the 
shielding blocks and field borders, such as the sphenoid 
sinus behind the pituitary shield, parapharyngeal region, 
and posterior skull base, which would be under-dosed 
when two-dimensional conventional radiotherapy is 
applied [27]. Thus, IMRT leads to improved local control 
in these areas. Second, MRI improves visualization and 
is superior to CT for identifying parapharyngeal tumor 
extension, skull base extension, and intracranial involve-
ment [13]. Therefore, a more precise dose of radiation 
can be delivered to the gross target volume of primary 
tumor, which ultimately improves local control for these 
areas. However, orbit extension, which usually occurs as 
tumor extension from the pterygopalatine fossa via the 
inferior orbital fissure or directly from the cavernous 
sinus, is a marker of the most severe extension of NPC 
[15]. Even with the most sophisticated treatment tech-
niques and intensive use of chemotherapy, some patients 
with advanced T4 disease that approaches important 
organs at risk cannot tolerate a radiation dose of 70 Gy, 
and the local control rate for this subgroup remains low, 
even after IMRT [28]. Some patients who had tiny intrac-
ranial extensions (for example, through the oval foramen 
or foramen lacerum to cavernous sinus) or cranial nerve 
palsy and did not have disease approaching important 
organs at risk were still able to tolerate a radiation dose 
of 70  Gy and achieve excellent local control. This find-
ing might explain why orbit involvement alone and not 
intracranial extension or cranial nerve palsy was the only 
independent prognostic factor for local control.
In patients diagnosed using CT and treated with con-
ventional radiotherapy, parapharyngeal tumor extension, 
skull base extension, cranial nerve palsy, retropharyngeal 
lymph node involvement, and all cervical lymph node-
related parameters (i.e., laterality, size, Ho’s location, and 
Fig. 2 Survival curves of 749 patients with NPC who were treated 
with IMRT. The current 7th edition of the Union for International 
Cancer Control/American Joint Committee on Cancer (UICC/AJCC) 
staging system was used for staging. a The 5‑year local relapse‑free 
survival (LRFS) rates for patients with stage T1‑T4 NPC were 98.4, 96.2, 
93.0, and 90.5%, respectively. b The 5‑year distant metastasis‑free 
survival (DMFS) rates for patients with stage N0‑N3b NPC were 93.3, 
84.2, 72.4, 61.9, and 50.7%, respectively. c the 5‑year overall survival 
(OS) rates for patients with stage I‑IVb NPC were 97.4, 93.8, 81.8, 69.7, 
and 54.0%, respectively
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fixity) were proved to be significant prognostic factors 
for distant control [22, 29]. In the present study, patients 
were diagnosed using MRI and treated with IMRT, and 
parapharyngeal tumor extension and all N stage-related 
parameters (i.e., retropharyngeal lymph node involve-
ment as well as the laterality, size, and Ho’s location of 
involved cervical lymph nodes) remained prognostic sig-
nificance for DMFS. A number of studies have confirmed 
that IMRT has improved local control but not distant 
control in NPC [8, 10, 28]. Thus, most of the parameters 
that influence distant control have not been altered by 
the introduction of IMRT.
Compared with previous studies, one major different 
finding in the present study is that intracranial extension 
rather than cranial nerve palsy was a significant prog-
nostic factor for distant control. Intracranial extension, 
which was defined as the involvement of the cavernous 
sinus, brain tissue, cistern, or dural meninges and could 
not be easily detected by CT, could be demonstrated 
more precisely by MRI because of its better tissue con-
trast and multiplanar capacity [13]. It has been reported 
that most patients with clinical cranial nerve palsy display 
one or more sites of intracranial involvement on MRI 
[30]. Therefore, the previously demonstrated adverse 
prognostic significance of cranial nerve palsy may be 
accurately reflected by intracranial extension on MRI.
Another difference was the lack of significant prognos-
tic value for skull base extension in terms of DMFS in the 
present study. It has been reported that 51.2% of patients 
with skull base extension shown on MRI but not on CT 
images had minimal bone disease [13]. These patients 
would have a more favorable prognosis [31, 32]. Although 
the diagnosis of skull base extension based entirely on MRI 
leads to an upstaging according to the UICC/AJCC stag-
ing system, skull base extension has not been confirmed 
as a significant prognostic factor for DMFS. However, the 
prognostic value of MRI-detected skull base extension var-
ies in different studies; although MRI-detected skull base 
extension was not an independent prognostic factor, the 
grading of skull base extension according to the site of 
extension has previously been reported to be an independ-
ent prognostic factor for both OS and DMFS [33].
The prognosis of a patient with cancer depends on 
the biological aggressiveness of the tumor, host factors, 
and therapeutic interventions [9]. However, we explored 
the prognosis only according to anatomic factors in this 
study. An increasing number of biological, genetic, and 
molecular factors, such as plasma/serum Epstein–Barr 
virus (EBV) DNA [34] and specific microRNAs (miR-
NAs) [35], as well as the target volume [36, 37] and other 
non-anatomic factors, have been identified and studied 
[38]. Such factors may have profound influences on the 
prognosis for individual patients. However, the extent of 
local extension, regional lymphatic spread, and distant 
metastasis as reflected by TNM staging still remain the 
most important prognostic factors in NPC [9].
Table 4 Multivariate prognostic analyses of anatomic factors in the 749 patients with NPC
HR hazard ratio, CI confidence interval, CCRT current chemoradiotherapy
Variable Disease failure Local failure Distant failure
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (>50 vs. ≤50 years) 1.857 (1.365–2.516) <0.001 0.996 (0.476–2.080) 0.997 1.433 (0.967–2.120) 0.074
Histological type (WHO II/III vs. WHO I) 1.371 (0.829–2.264) 0.221 0.843 (0.327–2.125) 0.710 3.614 (1.804–7.219) <0.001
Chemotherapy (CCRT, induction with CCRT, and CCRT 
with adjuvant vs. none)
1.207 (0.794–1.843) 0.383 0.624 (0.273–1.410) 0.269 1.459 (0.834–2.569) 0.190
Nasal cavity involvement (yes vs. no) 0.946 (0.683–1.311) 0.741 0.867 (0.429–1.752) 0.690 0.818 (0.547–1.225) 0.330
Oropharyngeal involvement (yes vs. no) 1.208 (0.812–1.798) 0.431 (0.130–1.432) 0.169 1.491 (0.941–2.362) 0.089
Parapharyngeal involvement (yes vs. no) 1.843 (1.144–2.969) 0.011 2.212 (0.690–7.141) 0.172 2.040 (1.115–3.764) 0.017
Skull base involvement (yes vs. no) 1.273 (0.851–1.906) 0.240 2.113 (0.790–5.651) 0.136 1.248 (0.759–2.052) 0.383
Paranasal sinus involvement (yes vs. no) 1.078 (0.704–1.650) 0.729 1.246 (0.526–2.949) 0.617 0.937 (0.543–1.616) 0.815
Cranial nerve involvement (yes vs. no) 1.394 (0.867–2.178) 0.139 2.012 (0.833–4.881) 0.120 1.247 (0.703–2.218) 0.399
Intracranial involvement (yes vs. no) 1.303 (0.871–1.950) 0.198 1.119 (0.468–2.674) 0.800 1.538 (1.056–2.490) 0.040
Infratemporal fossa involvement (yes vs. no) 1.035 (0.564–1.875) 0.893 0.616 (0.175–2.137) 0.458 0.737 (0.320–1.675) 0.467
Orbit involvement (yes vs. no) 1.641 (0.914–2.937) 0.109 4.067 (1.369–12.103) 0.011 1.537 (0.733–3.231) 0.251
Retropharyngeal lymph node involvement (yes vs. no) 1.583 (1.102–2.273) 0.011 1.519 (0.679–3.406) 0.309 1.565 (1.078–2.499) 0.030
Cervical lymph node involvement
 Longest diameter (>6 cm vs. ≤6 cm) 2.829 (1.603–4.991) <0.001 0.815 (0.107–6.219) 0.840 3.050 (1.625–5.727) 0.001
 Laterality (bilateral vs. unilateral) 1.475 (1.031–2.107) 0.032 0.398 (0.672–6.513) 0.423 1.625 (1.078–2.453) 0.019
 Ho’s location (Ho’s vs. above Ho’s) 2.396 (1.435–3.996) 0.001 0.567 (0.073–4.272) 0.583 2.859 (1.617–5.061) <0.001
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Because the definition of parapharyngeal tumor exten-
sion has differed substantially across different time 
points [26, 39], it is difficult to compare the prognos-
tic value of parapharyngeal tumor extension. This was 
a retrospective study that aimed to evaluate the prog-
nostic value of staging parameters amid the changes in 
diagnostic and therapeutic methods. Moreover, due to 
financial factors and some patients’ lack of health insur-
ance, PET/CT was only performed on 130 (25.4%) of the 
749 patients in our study. Additional effects of sensitive 
and specific imaging technologies such as PET on stage 
migration are expected. With its well-recognized supe-
riority in the detection of nodal metastases and distant 
metastases [40, 41], there seems to be little doubt that 
the addition of PET (with or without CT) could contrib-
ute to improve staging accuracy and prognostication in 
NPC.
Conclusions
The key failure pattern for NPC in the IMRT era was 
distant metastasis. With the changes in diagnostic and 
therapeutic technologies, the significant prognostic 
parameters for local control have also altered substan-
tially. Orbit involvement was the only independent prog-
nostic factor for local control, and intracranial extension, 
parapharyngeal tumor extension, and all N stage-related 
parameters were independent prognostic factors for 
DMFS.
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